Education
About Us
Working with TipRanks
Follow Us
Biotest (0N6Z) (DE:BIO)
:BIO
Top Page
Biotest
(LSE:BIO)
Rating:68Neutral
Price Target:―
Biotest (BIO) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.40B
Dividend Yield0.09%
Average Volume (3M)161.00
Price to Earnings (P/E)64.1
Beta (1Y)-0.08
Revenue Growth-18.82%
EPS Growth-113.85%
CountryDE
Employees2,495
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,785,727
10 Day Avg. Volume98
30 Day Avg. Volume161
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)2.97
Price to Sales (P/S)0.00
P/FCF Ratio42.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biotest Business Overview & Revenue Model
Company DescriptionBiotest AG is a Germany-based biotechnology company specializing in the development and production of plasma protein therapies and biotherapeutic drugs. The company operates primarily in the healthcare sector, focusing on products for clinical immunology, hematology, and intensive care medicine. Biotest's core products include immunoglobulins, clotting factors, and albumin solutions, which are used in treating various life-threatening diseases and conditions.
How the Company Makes MoneyBiotest generates revenue through the manufacturing and sale of plasma protein products and biotherapeutic drugs. The company's key revenue streams include sales of immunoglobulins, which are essential for patients with immune deficiencies; clotting factors used for treating hemophilia and other bleeding disorders; and albumin solutions used in intensive care settings. Biotest also engages in research and development activities aimed at expanding its product portfolio and improving existing therapies. Strategic partnerships and collaborations with other pharmaceutical and biotechnology firms can also contribute to its earnings by facilitating market expansion and distribution of its products.
Biotest Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 726.20M | 684.60M | 516.10M | 515.60M | 484.20M | Gross Profit |
| 223.80M | 280.30M | 124.90M | 80.70M | 130.10M | EBIT |
| 94.50M | 143.50M | -13.00M | -52.10M | -13.20M | EBITDA |
| 120.40M | 179.00M | 28.30M | -17.70M | 16.00M | Net Income Common Stockholders |
| 26.40M | 127.00M | -31.60M | -63.30M | -31.40M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 119.50M | 118.50M | 136.60M | 117.50M | 89.20M | Total Assets |
| 1.43B | 1.41B | 1.20B | 1.10B | 1.13B | Total Debt |
| 597.20M | 689.80M | 574.30M | 496.30M | 469.10M | Net Debt |
| 489.40M | 581.70M | 457.70M | 391.90M | 397.80M | Total Liabilities |
| 903.30M | 912.00M | 831.90M | 723.80M | 689.70M | Stockholders Equity |
| 530.70M | 498.90M | 371.10M | 380.40M | 441.60M |
| Cash Flow | Free Cash Flow | |||
| 32.20M | -36.10M | -69.80M | 15.70M | -43.70M | Operating Cash Flow |
| 60.90M | -2.70M | -40.50M | 33.90M | -16.70M | Investing Cash Flow |
| -25.70M | 1.30M | -37.00M | -23.40M | -14.60M | Financing Cash Flow |
| -35.40M | -6.80M | 89.60M | 22.60M | 42.00M |
Biotest Technical Analysis
Neutral
42.20
Price Trends
42.50
Negative
41.81
Positive
41.70
Positive
Market Momentum
<0.01
Positive
41.65
Neutral
30.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Neutral. The current price of 42.2 is below the 20-day moving average (MA) of 42.73, below the 50-day MA of 42.50, and above the 200-day MA of 41.70, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.65 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:BIO.
Biotest Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | €311.17M | 20.38 | 2.99% | ― | 5.62% | -21.87% | |
78 Outperform | €1.35B | 39.33 | 17.48% | 0.08% | 15.89% | 14.62% | |
68 Neutral | €1.40B | 64.15 | -4.72% | 0.09% | -18.82% | -113.85% | |
63 Neutral | €484.01M | 5.89 | -26.06% | ― | -10.32% | -250.76% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
49 Neutral | €1.25B | ― | -20.51% | ― | 1.50% | -127.76% |
* Healthcare Sector Average
Performance Comparison
DE:BIO
Biotest
42.20
1.40
3.43%
DE:EVT
Evotec
7.16
-1.71
-19.30%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
66.75
24.76
58.95%
DE:ILM1
Medios AG
12.02
-4.08
-25.34%
DE:FYB
Formycon AG
28.65
-19.85
-40.93%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.